Skip to main content
Springer Nature Link
Log in

In Vitro Characterization of Hepatic Flavopiridol Metabolism Using Human Liver Microsomes and Recombinant UGT Enzymes

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To assess the contribution of drug metabolism to the variability on flavopiridol glucuronidation observed in cancer patients, and to determine the ability of all known human UDP-glucuronosyltransferase (UGT) isoforms to glucuronidate flavopiridol.

Methods. Inter-individual variation in flavopiridol glucuronidation was determined by HPLC using hepatic microsomes from 62 normal liver donors. Identification of enzymes capable of glucuronidating flavopiridol was determined by LC/MS using human embryonic kidney 293 (HEK293) cells stably expressing all sixteen known human UGTs.

Results. The major product of the flavopiridol glucuronidation reaction in human liver microsomes was FLAVO-7-G. High variability (coefficient of variation = 49%) was observed in the glucuronidation of flavopiridol by human liver microsomes. In vitro formation of FLAVO-7-G and FLAVO-5-G was mainly catalyzed by UGT1A9 and UGT1A4, respectively. Similar catalytic efficiencies (Vmax/Km) were observed for human liver microsomes (1.6 μl/min/mg) and UGT1A9 (1.5 μl/min/mg).

Conclusions. UGT1A9 is the major UGT involved in the hepatic glucuronidation of flavopiridol in humans. The data suggests that hepatic glucuronidation may be a major determinant of the variable systemic glucuronidation of flavopiridol in cancer patients. The large variability in flavopiridol glucuronidation may be due to differences in liver metabolism among individuals, as a result of genetic differences in UGT1A9.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. B. A. Carlson, M. M. Dubay, E. A. Sausville, L. Brizuela, and P. J. Worland. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56:2973–2978 (1996).

    Google Scholar 

  2. A. M. Senderowicz, D. Headlee, S. F. Stinson, R. M. Lush, N. Kalil, L. Villalba, K. Hill, S. M. Steinberg, W. D. Figg, A. Tompkins, S. G. Arbuck, and E. A. Sausville. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J.Clin.Oncol. 16:2986–2999 (1998).

    Google Scholar 

  3. W. M. Stadler, N. J. Vogelzang, R. Amato, J. Sosman, D. Taber, D. Liebowitz, and E. E. Vokes. Flavopiridol, a novel cyclindependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium study. J.Clin.Oncol. 18: 371–375 (2000).

    Google Scholar 

  4. W. Jager, B. Zembsch, P. Wolschann, E. Pittenauer, A. M. Senderowicz, E. A. Sausville, H. H. Sedlacek, J. Graf, and T. Thalhammer. Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver. Life Sci. 62: 1861–1873 (1998).

    Google Scholar 

  5. F. Innocenti, W. M. Stadler, L. Iyer, J. Ramirez, E. E. Vokes, and M. J. Ratain. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin.Cancer Res. 6:3400–3405 (2000).

    Google Scholar 

  6. M. D. Green, E. M. Oturu, and T. R. Tephly. Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. Drug Metab.Dispos. 22:799–805 (1994).

    Google Scholar 

  7. A. Radominska-Pandya, P. J. Czernik, J. M. Little, E. Battaglia, and P. I. Mackenzie. Structural and functional studies of UDPglucuronosyltransferases. Drug Metab.Rev. 31:817–899 (1999).

    Google Scholar 

  8. P. I. Mackenzie, I. S. Owens, B. Burchell, K. W. Bock, A. Bairoch, A. Belanger, S. Fournel-Gigleux, M. Green, D. W. Hum, T. Iyagani, D. Lancet, P. Louisot, J. Magdalou, J. R. Chowdhury, J. K. Ritter, H. Schachter, T. R. Tephly, K. F. Tipton, and D. W. Nebert. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 7:255–269 (1997).

    Google Scholar 

  9. R. H. Tukey and C. P. Strassburg. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu.Rev.Pharmacol.Toxicol. 40:581–616 (2000).

    Google Scholar 

  10. E. Levesque, D. Turgeon, J. S. Carrier, V. Montminy, M. Beaulieu, and A. Belanger. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase. Biochemistry 40:3869–3881 (2001).

    Google Scholar 

  11. B. Hagenauer, A. Salamon, T. Thalhammer, O. Kunert, E. Haslinger, P. Klingler, A. M. Senderowicz, E. A. Sausville, and W. Jager. In Vitro Glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9. Drug Metab.Dispos. 29:407–414 (2001).

    Google Scholar 

  12. H. S. Purba, J. L. Maggs, M. L. Orme, D. J. Back, and B. K. Park. The metabolism of 17 alpha-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites. Br.J.Clin.Pharmacol. 23:447–453 (1987).

    Google Scholar 

  13. M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal.Biochem. 72:248–254 (1976).

    Google Scholar 

  14. C. Guillemette, J. K. Ritter, D. J. Auyeung, F. K. Kessler, and D. E. Housman. Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics 10:629–644 (2000).

    Google Scholar 

  15. C. Albert, M. Vallee, G. Beaudry, A. Belanger, and D. W. Hum. The monkey and human uridine diphosphate-glucuronosyltransferase UGT1A9, expressed in steroid target tissues, are estrogen-conjugating enzymes. Endocrinology 140:3292–3302 (1999).

    Google Scholar 

  16. E. Levesque, M. Beaulieu, M. D. Green, T. R. Tephly, A. Belanger, and D. W. Hum. Isolation and characterization of UGT2B15 (Y85): a UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7:317–325 (1997).

    Google Scholar 

  17. F. P. Guengerich, A. Parikh, E. F. Johnson, T. H. Richardson, C. von Wachenfeldt, J. Cosme, F. Jung, C. P. Strassburg, M. P. Manns, R. H. Tukey, M. Pritchard, S. Fournel-Gigleux, and B. Burchell. Heterologous expression of human drug-metabolizing enzymes. Drug Metab.Dispos. 25:1234–1241 (1997).

    Google Scholar 

  18. W. W. Weber. The legacy of pharmacogenetics and potential applications. Mutat.Res. 473:1–18 (2001).

    Google Scholar 

  19. F. Innocenti, L. Iyer, and M. J. Ratain. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab.Dispos. 29:596–600 (2001).

    Google Scholar 

  20. P. A. Gregory, A. J. Hansen, and P. I. Mackenzie. Tissue specific differences in the regulation of the UDP glucuronosyltransferase 2B17 gene promoter. Pharmacogenetics 10:809–820 (2000).

    Google Scholar 

  21. J. A. Boutin, F. Meunier, P. H. Lambert, P. Hennig, D. Bertin, B. Serkiz, and J. P. Volland. In vivo and in vitro glucuronidation of the flavonoid diosmetin in rats. Drug Metab.Dispos. 21:1157–1166 (1993).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Chicago, Chicago, Illinois

    Jacqueline Ramírez

  2. Department of Medicine, Committee on Clinical Pharmacology, Cancer Research Center, University of Chicago, Chicago, Illinois

    Lalitha Iyer, Federico Innocenti & Mark J. Ratain

  3. Oncology and Molecular Endocrinology Research Center, CHUL Research Center, Faculty of Pharmacy, Laval University, Québec, Canada

    Kim Journault & Patrick Bélanger

Authors
  1. Jacqueline Ramírez
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Lalitha Iyer
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Kim Journault
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Patrick Bélanger
    View author publications

    You can also search for this author inPubMed Google Scholar

  5. Federico Innocenti
    View author publications

    You can also search for this author inPubMed Google Scholar

  6. Mark J. Ratain
    View author publications

    You can also search for this author inPubMed Google Scholar

  7. Chantal Guillemette
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Mark J. Ratain.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramírez, J., Iyer, L., Journault, K. et al. In Vitro Characterization of Hepatic Flavopiridol Metabolism Using Human Liver Microsomes and Recombinant UGT Enzymes. Pharm Res 19, 588–594 (2002). https://doi.org/10.1023/A:1015341726183

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1015341726183

Profiles

  1. Chantal Guillemette View author profile